Health Discovery Corporation and Atlantic Alpha Strategies, LLC Announce Formation of Joint Venture.

New Company Will Apply HDC's State-of-the-Art Support Vector Machine Technology to Quantitative Investment Analysis

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today that it had entered into a binding agreement with Atlantic Alpha Strategies, LLC ("A-A") to explore and exploit the potential applicability of HDC's Support Vector Machines ("SVM") to quantitative investment management techniques. An equally owned joint venture, SVM Capital LLC, will be formed to advance these objectives. Among other considerations, HDC will contribute a worldwide exclusive license for the use of SVMs in financial markets and A-A will contribute an historical database for equity, debt, currency and commodities markets.

"To date, our research with HDC is a highly promising start towards our goal of a superior risk-to-reward investment model," said Mark Moore, Ph.D., a founding partner of A-A and the President of SVM Capital. "Our preliminary findings indicate not only higher than average returns but also major reductions in volatility. These results are quite remarkable considering that we are still at a very early stage of development and have not yet fully implemented all of the technological advantages of the SVM algorithms."

According to William F. Quirk, Jr., a member of HDC's Board of Directors, "We've always known that SVM pattern recognition applications far transcend the pharma/biotech arena that has thus far defined HDC, and our patents actually reflect this fact. Hundreds of studies in medical research confirm the consistent superiority of SVMs to other popular mathematical tools, such as neural networks, that are widely used in quantitative investment techniques. If SVM Capital can now develop predictive financial models and if these performance differentials can be maintained, it could signal a major advance in investment management and hedging techniques that cannot be duplicated because of our patent protection."

"HDC is most fortunate to partner with a financial markets domain expert such as Mark Moore," noted Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "This arrangement brings an entirely new dimension to HDC's technology portfolio by demonstrating our willingness to work with firms outside the medical arena to leverage our technological strengths without overextending our management capabilities. Joint ventures such as this can create new and exciting revenue opportunities for HDC which may prove quite beneficial for our shareholders."

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

Atlantic-Alpha Strategies was founded in 2006 to manage a fully-hedged equity arbitrage fund based on Dr. Moore's proprietary Pairs Trading program. This in turn is the culmination of his particular expertise in developing specialized logic structures for value decisions in financial markets since he became a General Partner (1988-1992) of Millennium Partners, an international hedge fund. Dr. Moore's career has been focused on quantitative approaches for a variety of investment vehicles in the options, commodities, equities and debt markets.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.